 |
|
Glucose-Insulin-Potassium Therapy in Patients With ST-Segment Elevation Myocardial Infarction
Rafael Díaz, MD;
Abhinav Goyal, MD, MHS;
Shamir R. Mehta, MD, MSc;
Rizwan Afzal, MSc;
Denis Xavier, MD;
Prem Pais, MD, MSc;
Susan Chrolavicius, RN, BA;
Jun Zhu, MD;
Khawar Kazmi, MD;
Lisheng Liu, MD;
Andrzej Budaj, MD, PhD;
Mohammad Zubaid, MD;
Alvaro Avezum, MD, PhD;
Mikhail Ruda, MD;
Salim Yusuf, MBBS, DPhil
JAMA. 2007;298(20):2399-2405.
Context The clinical benefit of glucose-insulin-potassium (GIK) infusion in patients with ST-segment elevation myocardial infarction (STEMI) is unclear. While some smaller trials suggest benefit, in the CREATE-ECLA trial, GIK infusion had no effect on 30-day mortality in 20 201 patients.
Objectives To determine the association between GIK infusion therapy and 30-day and 6-month outcomes in patients with STEMI.
Design, Setting, and Participants Primary analysis of the OASIS-6 GIK randomized controlled trial of 2748 patients with acute STEMI; prespecified analyses of the combined trial data from the OASIS-6 GIK and CREATE-ECLA GIK trial populations of 22 943 patients with acute STEMI; subgroup analysis on the timing of initiation of GIK infusion therapy and outcomes; and post hoc analyses exploring whether GIK infusion may cause early harm by increasing glucose and potassium levels and net fluid gain.
Intervention High-dose GIK solution consisting of 25% glucose, 50 U/L of regular insulin, and 80 mEq/L of potassium infused at 1.5 mL/kg per hour for 24 hours.
Main Outcome Measures Mortality rates at 30 days and 6 months in the OASIS-6 GIK trial and rates of death, heart failure, and the composite of death or heart failure at 3 and 30 days in the combined OASIS-6 GIK and CREATE-ECLA GIK trial populations.
Results At 6 months, 148 (10.8%) GIK infusion patients and 143 (10.4%) control patients died in the OASIS-6 trial (hazard ratio [HR], 1.04; 95% CI, 0.83-1.31; P = .72); 153 (11.1%) GIK patients and 185 (13.5%) control patients had heart failure (HR, 0.83; 95% CI, 0.67-1.02; P = .08); and 240 (17.5%) GIK patients and 264 (19.2%) control patients had a composite of death or heart failure (HR, 0.91; 95% CI, 0.76-1.08; P = .27). In the prespecified analyses of the combined trial data, there were 712 deaths (6.2%) in the GIK group and 632 deaths (5.5%) in the control group at 3 days (HR, 1.13; 95% CI, 1.02-1.26; P = .03). This difference disappeared by 30 days, with 1108 deaths (9.7%) in the GIK group and 1068 (9.3%) in the control group (HR, 1.04; 95% CI, 0.96-1.13; P = .33). GIK therapy increased levels of glucose, potassium, and net fluid gain postinfusion, all 3 of which predicted death after adjusting for multiple confounders. Adjusting for glucose, potassium, and net fluid gain eliminated the apparent increase in mortality at 3 days observed with GIK infusion, suggesting a direct association with these factors. Administration of GIK infusion within 4 hours of symptom onset yielded no benefit compared with later initiation.
Conclusions Infusion of GIK provided no benefit and may cause early harm following STEMI. Avoidance of infusion-related hyperglycemia, hyperkalemia, and net fluid gain may be advisable in future studies of metabolic modulation in patients with STEMI.
Trial Registration clinicaltrials.gov Identifier: NCT00064428
Author Affiliations: Etudios Cardiologica Latin America, Rosario, Argentina (Dr Díaz); Department of Epidemiology, Emory Rollins School of Public Health and Emory School of Medicine, Atlanta, Georgia (Dr Goyal); Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada (Drs Goyal, Mehta, Xavier, and Yusuf, Mr Afzal, and Ms Chrolavicius); Department of Medicine, McMaster University, Hamilton, Ontario, Canada (Drs Mehta and Yusuf, Mr Afzal, and Ms Chrolavicius); St John's Medical College National Academy of Health Sciences, Bangalore, India (Drs Xavier and Pais); Cardiovascular Institute and Fu Wai Hospital, Chinese Hypertension League Institute, Beijing, China (Drs Zhu and Liu); Aga Khan University, Karachi, Pakistan (Dr Kazmi); Postgraduate Medical School, Department of Cardiology, Grochowski Hospital, Warsaw, Poland (Dr Budaj); Mubarak Al-Kabeer Hospital, Safat, Kuwait (Dr Zubaid); Dante Pazzanese Cardiology Institute, São Paulo, Brazil (Dr Avezum); and Cardiology Research Center, Moscow, Russia (Dr Ruda).
RELATED LETTERS
Glucose-Insulin-Potassium Therapy in Patients With STEMI
Harry P. Selker, Joanne Ingwall, and Charles E. Rackley
JAMA. 2008;299(20):2385.
EXTRACT
| FULL TEXT
Glucose-Insulin-Potassium Therapy in Patients With STEMI
Lionel H. Opie
JAMA. 2008;299(20):2385-2386.
EXTRACT
| FULL TEXT
Glucose-Insulin-Potassium Therapy in Patients With STEMI
Rohit R. Arora and Srikanth Katragadda
JAMA. 2008;299(20):2386.
EXTRACT
| FULL TEXT
Glucose-Insulin-Potassium Therapy in Patients With STEMI
Ajay Chaudhuri, Richard Nesto, and Paresh Dandona
JAMA. 2008;299(20):2386-2387.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38
Wiviott et al.
Circulation 2008;118:1626-1636.
ABSTRACT
| FULL TEXT
Hyperglycemia Is Associated With Enhanced Thrombin Formation, Platelet Activation, and Fibrin Clot Resistance to Lysis in Patients With Acute Coronary Syndrome
Undas et al.
Diabetes Care 2008;31:1590-1595.
ABSTRACT
| FULL TEXT
The malonyl CoA axis as a potential target for treating ischaemic heart disease
Ussher and Lopaschuk
Cardiovasc Res 2008;79:259-268.
ABSTRACT
| FULL TEXT
The year in interventional cardiology.
Dixon et al.
J Am Coll Cardiol 2008;51:2355-2369.
FULL TEXT
Glucose-Insulin-Potassium Therapy in Patients With STEMI
Selker et al.
JAMA 2008;299:2385-2385.
FULL TEXT
Glucose-Insulin-Potassium Therapy in Patients With STEMI
Arora and Katragadda
JAMA 2008;299:2386-2386.
FULL TEXT
Glucose-Insulin-Potassium Therapy in Patients With STEMI
Opie
JAMA 2008;299:2385-2386.
FULL TEXT
Glucose-Insulin-Potassium Therapy in Patients With STEMI
Chaudhuri et al.
JAMA 2008;299:2386-2387.
FULL TEXT
Glucose-Insulin-Potassium for Acute Myocardial Infarction: Continuing Controversy Over Cardioprotection
Kloner and Nesto
Circulation 2008;117:2523-2533.
FULL TEXT
Metabolic Management of Acute Myocardial Infarction Comes to the Fore and Extends Beyond Control of Hyperglycemia
Opie
Circulation 2008;117:2172-2177.
FULL TEXT
Glucose: A Biomarker in Acute Myocardial Infarction Ready for Prime Time?
Nesto and Lago
Circulation 2008;117:990-992.
FULL TEXT
What's new in the other general journals
BMJ 2007;335:1178-1179.
FULL TEXT
Glucose-Insulin-Potassium Infusion May Cause Early Harm After STEMI
Journal Watch Cardiology 2007;2007:1-1.
FULL TEXT
|
